共查询到20条相似文献,搜索用时 578 毫秒
1.
Isabel Molina-Ortiz Rub��n A. Bartolom�� Pablo Hern��ndez-Varas Georgina P. Colo Joaquin Teixid�� 《The Journal of biological chemistry》2009,284(22):15147-15157
Melanoma cells express the chemokine receptor CXCR4 that confers high
invasiveness upon binding to its ligand CXCL12. Melanoma cells at initial
stages of the disease show reduction or loss of E-cadherin expression, but
recovery of its expression is frequently found at advanced phases. We
overexpressed E-cadherin in the highly invasive BRO lung metastatic cell
melanoma cell line to investigate whether it could influence CXCL12-promoted
cell invasion. Overexpression of E-cadherin led to defective invasion of
melanoma cells across Matrigel and type I collagen in response to CXCL12. A
decrease in individual cell migration directionality toward the chemokine and
reduced adhesion accounted for the impaired invasion. A p190RhoGAP-dependent
inhibition of RhoA activation was responsible for the impairment in
chemokine-stimulated E-cadherin melanoma transfectant invasion. Furthermore,
we show that p190RhoGAP and p120ctn associated predominantly on the plasma
membrane of cells overexpressing E-cadherin, and that E-cadherin-bound p120ctn
contributed to RhoA inactivation by favoring p190RhoGAP-RhoA association.
These results suggest that melanoma cells at advanced stages of the disease
could have reduced metastatic potency in response to chemotactic stimuli
compared with cells lacking E-cadherin, and the results indicate that
p190RhoGAP is a central molecule controlling melanoma cell invasion.Cadherins are a family of Ca2+-dependent adhesion molecules that
mediate cell-cell contacts and are expressed in most solid tissues providing a
tight control of morphogenesis
(1,
2). Classical cadherins, such
as epithelial (E) cadherin, are found in adherens junctions, forming core
protein complexes with β-catenin, α-catenin, and p120 catenin
(p120ctn). Both β-catenin and p120ctn directly interact with E-cadherin,
whereas α-catenin associates with the complex through its binding to
β-catenin, providing a link with the actin cytoskeleton
(1,
2). E-cadherin is frequently
lost or down-regulated in many human tumors, coincident with morphological
epithelial to mesenchymal transition and acquisition of invasiveness
(3-6).Although melanoma only accounts for 5% of skin cancers, when metastasis
starts, it is responsible for 80% of deaths from skin cancers
(7). Melanocytes express
E-cadherin
(8-10),
but melanoma cells at early radial growth phase show a large reduction in the
expression of this cadherin, and surprisingly, expression has been reported to
be partially recovered by vertical growth phase and metastatic melanoma cells
(9,
11,
12).Trafficking of cancer cells from primary tumor sites to intravasation into
blood circulation and later to extravasation to colonize distant organs
requires tightly regulated directional cues and cell migration and invasion
that are mediated by chemokines, growth factors, and adhesion molecules
(13). Solid tumor cells
express chemokine receptors that provide guidance of these cells to organs
where their chemokine ligands are expressed, constituting a homing model
resembling the one used by immune cells to exert their immune surveillance
functions (14). Most solid
cancer cells express CXCR4, a receptor for the chemokine CXCL12 (also called
SDF-1), which is expressed in lungs, bone marrow, and liver
(15). Expression of CXCR4 in
human melanoma has been detected in the vertical growth phase and on regional
lymph nodes, which correlated with poor prognosis and increased mortality
(16,
17). Previous in vivo
experiments have provided evidence supporting a crucial role for CXCR4 in the
metastasis of melanoma cells
(18).Rho GTPases control the dynamics of the actin cytoskeleton during cell
migration (19,
20). The activity of Rho
GTPases is tightly regulated by guanine-nucleotide exchange factors
(GEFs),4 which
stimulate exchange of bound GDP by GTP, and inhibited by GTPase-activating
proteins (GAPs), which promote GTP hydrolysis
(21,
22), whereas guanine
nucleotide dissociation inhibitors (GDIs) appear to mediate blocking of
spontaneous activation (23).
Therefore, cell migration is finely regulated by the balance between GEF, GAP,
and GDI activities on Rho GTPases. Involvement of Rho GTPases in cancer is
well documented (reviewed in Ref.
24), providing control of both
cell migration and growth. RhoA and RhoC are highly expressed in colon,
breast, and lung carcinoma
(25,
26), whereas overexpression of
RhoC in melanoma leads to enhancement of cell metastasis
(27). CXCL12 activates both
RhoA and Rac1 in melanoma cells, and both GTPases play key roles during
invasion toward this chemokine
(28,
29).Given the importance of the CXCL12-CXCR4 axis in melanoma cell invasion and
metastasis, in this study we have addressed the question of whether changes in
E-cadherin expression on melanoma cells might affect cell invasiveness. We
show here that overexpression of E-cadherin leads to impaired melanoma cell
invasion to CXCL12, and we provide mechanistic characterization accounting for
the decrease in invasion. 相似文献
2.
3.
4.
Lilly Y. W. Bourguignon Weiliang Xia Gabriel Wong 《The Journal of biological chemistry》2009,284(5):2657-2671
5.
6.
7.
The actin cytoskeleton has an important role in the organization and
function of the immune synapse during antigen recognition. Dynamic
rearrangement of the actin cytoskeleton in response to T cell receptor (TCR)
triggering requires the coordinated activation of Rho family GTPases that
cycle between active and inactive conformations. This is controlled by
GTPase-activating proteins (GAP), which regulate inactivation of Rho GTPases,
and guanine exchange factors, which mediate their activation. Whereas much
attention has centered on guanine exchange factors for Rho GTPases in T cell
activation, the identity and functional roles of the GAP in this process are
largely unknown. We previously reported β2-chimaerin as a
diacylglycerol-regulated Rac-GAP that is expressed in T cells. We now
demonstrate Lck-dependent phosphorylation of β2-chimaerin in response to
TCR triggering. We identify Tyr-153 as the Lck-dependent phosphorylation
residue and show that its phosphorylation negatively regulates membrane
stabilization of β2-chimaerin, decreasing its GAP activity to Rac. This
study establishes the existence of TCR-dependent regulation of
β2-chimaerin and identifies a novel mechanism for its inactivation.T cell activation requires presentation of an antigen by antigen-presenting
cells (APC)2 to the T
cell receptor (TCR); this event involves the reorganization of several
scaffolds and signaling proteins, leading to formation of the immunological
synapse (IS) (1). Correct
protein redistribution during synapse formation is critical for an efficient T
cell response, and it is largely regulated by actin polymerization at the T
cell/APC contact site as a result of TCR-regulated Rac-dependent signals
(2,
3). Like other Rho GTPases, Rac
cycles between a GTP-bound active state and a GDP-bound inactive state. This
continuous recycling is regulated by the concerted action of two proteins as
follows: GEF, which activates Rac by mediating GDP/GTP exchange
(4), and GAP, which induces Rac
inactivation by accelerating intrinsic Rac GTPase activity, converting GTP to
GDP (5).Vav-1 is the best studied GEF for Rac, and it has critical roles in T
cell-dependent functions (6).
In naive, unstimulated T cells, Vav-1 is in an inactive state through
autoinhibition, as the GEF domain is blocked by the N-terminal region
(7). This autoinhibition is
relieved by TCR-mediated tyrosine phosphorylation
(8,
9). Thymocytes from
Vav-1-deficient mice have a developmental block, and their mature T cells show
severe defects in IS formation, as well as reduced Ca2+ influx,
IL-2 production, T cell proliferation, and cytotoxic activity
(10–13).
Although several studies have shown a key role for Vav-1, the mechanisms that
govern Rac inactivation downstream of the TCR remain elusive.The chimaerins are a family of Rho-GAP, with specific activity for Rac. In
addition to their catalytic domain, they have an N-terminal SH2 domain and a
C1 domain required for interaction with the lipid messenger diacylglycerol
(DAG) and with phorbol esters
(14). There are two mammalian
chimaerin genes (CHN1 and CHN2), which encode the
full-lengthα2-(ARHGAP2) and β2-chimaerins (ARHGAP3), and at least
one splice variant each (α1 and β1) that lack the SH2 domain. The
α-chimaerins are expressed abundantly in brain and are linked to
neuritogenesis and axon guidance
(15–20).
β2-Chimaerin expression is ubiquitous
(21) and is involved in
EGF-dependent Rac regulation
(22,
23). Experiments in T cells
showed that β2-chimaerin participates in chemokine-dependent regulation
of T cell migration and adhesion
(24). A very recent study
implicates chimaerins in the modulation of Rac activity during T cell synapse
formation, suggesting that this protein family contributes to DAG-mediated
regulation of cytoskeletal remodeling during T cell activation
(25).Determination of the β2-chimaerin crystal structure provided important
clues regarding its mechanism of action. In the absence of stimulation, the
protein is in an inactive state in which the N-terminal domain maintains a
“closed” conformation, blocking Rac binding and concealing the C1
domain (26). These structural
data were fully supported by experiments in live T lymphocytes showing that
phorbol myristate acetate (PMA)-dependent translocation of β2-chimaerin
was less effective than that of its isolated C1 domain
(24). These data not only
confirmed the lack of accessibility of the β2-chimaerin C1 domain but
also suggested that there are negative regulatory mechanisms that promote
β2-chimaerin release from the membrane.DAG-dependent signaling is critical for the modulation of T cell functions,
by virtue of its ability to bind and regulate C1 domain-containing proteins
such as protein kinase Cθ, protein kinase D, and RasGRP1
(27). An important issue is to
determine how the different DAG-binding proteins discriminate between distinct
DAG pools, and how DAG activates certain C1-containing proteins and not
others. Some mechanisms that allow discrimination between DAG receptors
include the distinct affinity of C1 domains for different DAG pools,
association of C1 domain-containing proteins to specific scaffolds, and/or
structural determinants in these proteins that limit C1 domain accessibility
to membrane DAG
(28–30).To explore the events that contribute to the specific regulation of
β2-chimaerin, we studied β2-chimaerin phosphorylation in the context
of TCR stimulation. We show that β2-chimaerin is phosphorylated in
tyrosine residues after TCR stimulation, and we identify Lck as the Tyr kinase
responsible for this phosphorylation. Generation of point mutants identified
Tyr-153, at the hinge of the SH2 and C1 domains, as the main tyrosine residue
phosphorylated in response to TCR stimulation. Cells expressing a
β2-chimaerin mutant defective for Tyr-153 phosphorylation show anomalies
in TCR clustering, conjugate formation, NF-AT activation, and IL-2 production
that correlate with elevated Rac-GAP activity in this mutant. Subcellular
localization analysis of the β2-chimaerin mutants reveals that impairment
of β2-chimaerin phosphorylation at Tyr-153 promotes C1-mediated
β2-chimaerin stabilization at the plasma membrane, providing a
mechanistic explanation for its higher Rac-GAP activity. In summary, our
results demonstrate for the first time that tyrosine kinase-mediated negative
regulation of β2-chimaerin is elicited by physiological stimulation in T
lymphocytes, and suggest that TCR stimulation provides both positive and
negative signals for β2-chimaerin activation. 相似文献
8.
Ivana I. Knezevic Sanda A. Predescu Radu F. Neamu Matvey S. Gorovoy Nebojsa M. Knezevic Cordus Easington Asrar B. Malik Dan N. Predescu 《The Journal of biological chemistry》2009,284(8):5381-5394
It is known that platelet-activating factor (PAF) induces severe
endothelial barrier leakiness, but the signaling mechanisms remain unclear.
Here, using a wide range of biochemical and morphological approaches applied
in both mouse models and cultured endothelial cells, we addressed the
mechanisms of PAF-induced disruption of interendothelial junctions (IEJs) and
of increased endothelial permeability. The formation of interendothelial gaps
filled with filopodia and lamellipodia is the cellular event responsible for
the disruption of endothelial barrier. We observed that PAF ligation of its
receptor induced the activation of the Rho GTPase Rac1. Following PAF
exposure, both Rac1 and its guanine nucleotide exchange factor Tiam1 were
found associated with a membrane fraction from which they
co-immunoprecipitated with PAF receptor. In the same time frame with
Tiam1-Rac1 translocation, the junctional proteins ZO-1 and VE-cadherin were
relocated from the IEJs, and formation of numerous interendothelial gaps was
recorded. Notably, the response was independent of myosin light chain
phosphorylation and thus distinct from other mediators, such as histamine and
thrombin. The changes in actin status are driven by the PAF-induced localized
actin polymerization as a consequence of Rac1 translocation and activation.
Tiam1 was required for the activation of Rac1, actin polymerization,
relocation of junctional associated proteins, and disruption of IEJs. Thus,
PAF-induced IEJ disruption and increased endothelial permeability requires the
activation of a Tiam1-Rac1 signaling module, suggesting a novel therapeutic
target against increased vascular permeability associated with inflammatory
diseases.The endothelial barrier is made up of endothelial cells
(ECs)4 connected to
each other by interendothelial junctions (IEJs) consisting of protein
complexes organized as tight junctions (TJs) and adherens junctions (AJs). In
addition, the focal adhesion complex located at the basal plasma membrane
enables firm contact of ECs with the underlying basement membrane and also
contributes to the barrier function
(1-3).
The glycocalyx, the endothelial monolayer, and the basement membrane all
together constitute the vascular barrier.The structural integrity of the ECs along with their proper functionality
are the two most important factors controlling the tightness of the
endothelial barrier. Changes affecting these factors cause loss of barrier
restrictiveness and leakiness. Therefore, defining and understanding the
cellular and molecular mechanisms controlling these processes is of paramount
importance. Increased width of IEJs in response to permeability-increasing
mediators (4) regulates the
magnitude of transendothelial exchange of fluid and solutes. Disruption of
IEJs and the resultant barrier leakiness contribute to the genesis of diverse
pathological conditions, such as inflammation
(5), metastasis
(6,
7), and uncontrolled
angiogenesis (8,
9).Accumulated evidence demonstrated that IEJs changes are responsible for
increased or decreased vascular permeability, and the generally accepted
mechanism responsible for them was the myosin light chain (MLC)-mediated
contraction of ECs (5,
10). However, published
evidence showed that an increase in vascular permeability could be obtained
without a direct involvement of any contractile mechanism
(11-16).The main component of the vascular barrier, the ECs, has more than 10% of
their total protein represented by actin
(17), which under
physiological salt concentrations subsists as monomers (G-actin) and assembled
into filaments (F-actin). A large number of actin-interacting proteins may
modulate the assembly, disassembly, and organization of G-actin and of actin
filaments within a given cell type. Similar to the complexity of
actin-interacting proteins found in other cell types, the ECs utilize their
actin binding proteins to stabilize the endothelial monolayer in order to
efficiently function as a selective barrier
(11). In undisturbed ECs, the
actin microfilaments are organized as different networks with distinctive
functional and morphological characteristics: the peripheral filaments also
known as peripheral dense band (PDB), the cytoplasmic fibers identified as
stress fibers (SF), and the actin from the membrane cytoskeleton
(18). The peripheral web,
localized immediately under the membrane, is associated with (i) the luminal
plasmalemma (on the apical side), (ii) the IEJ complexes on the lateral
surfaces, and (iii) the focal adhesion complexes on the abluminal side (the
basal part) of polarized ECs. The SF reside inside the endothelial cytoplasm
and are believed to be directly connected with the plasmalemma proper on the
luminal as well as on the abluminal side of the cell. As described, the
endothelial actin cytoskeleton (specifically the SF) seems to be a stable
structure helping the cells to remain flat under flow
(19). It is also established
that the actin fibers participate in correct localization of different
junctional complexes while keeping them in place
(20). However, it was
suggested that the dynamic equilibrium between F- and G-actin might modulate
the tightness of endothelial barrier in response to different challenges
(13).Mediators effective at nanomolar concentrations or less that disrupt the
endothelial barrier and increase vascular permeability include C2 toxin of
Clostridium botulinum, vascular permeability factor, better known as
vascular endothelial growth factor, and PAF
(21). C2 toxin increases
endothelial permeability by ribosylating monomeric G-actin at Arg-177
(22). This results in the
impairment of actin polymerization
(23), followed by rounding of
ECs (16) and the disruption of
junctional integrity. Vascular permeability factor was shown to open IEJs by
redistribution of junctional proteins
(24,
25) and by interfering with
the equilibrium of actin pools
(26). PAF
(1-O-alkyl-2-acetyl-sn-glycero-3-phosphocoline), a naturally
synthesized phospholipid is active at 10-10 m or less
(27). PAF is synthesized by
and acts on a variety of cell types, including platelets
(28), neutrophils
(29), monocytes
(30), and ECs
(31). PAF-mediated activation
of ECs induced cell migration
(32), angiogenesis
(7), and vascular
hyperpermeability (33)
secondary to disassembly of IEJs
(34). The effects of PAF on
the endothelium are initiated through a G protein-coupled receptor (PAF-R)
localized at the plasmalemma, in a large endosomal compartment inside the cell
(34), and also in the nuclear
membrane (35). In ECs, PAF-R
was shown to signal through Gαq and downstream activation of
phospholipase C isozymes (PLCβ3 and PLCγ1),
and via cSrc (32,
36). Studies have shown that
PAF challenge induced endothelial actin cytoskeletal rearrangement
(37) and marked vascular
leakiness (38); however, the
signaling pathways have not been elucidated.Therefore, in the present study, we carried out a systematic analysis of
PAF-induced morphological and biochemical changes of endothelial barrier
in vivo and in cultured ECs. We found that the opening of endothelial
barrier and the increased vascular leakiness induced by PAF are the result of
a shift in actin pools without involvement of EC contraction, followed by a
redistribution of tight junctional associated protein ZO-1 and adherens
junctional protein VE-cadherin. 相似文献
9.
Ruben K. Dagda Salvatore J. Cherra III Scott M. Kulich Anurag Tandon David Park Charleen T. Chu 《The Journal of biological chemistry》2009,284(20):13843-13855
Mitochondrial dysregulation is strongly implicated in Parkinson disease.
Mutations in PTEN-induced kinase 1 (PINK1) are associated with familial
parkinsonism and neuropsychiatric disorders. Although overexpressed PINK1 is
neuroprotective, less is known about neuronal responses to loss of PINK1
function. We found that stable knockdown of PINK1 induced mitochondrial
fragmentation and autophagy in SH-SY5Y cells, which was reversed by the
reintroduction of an RNA interference (RNAi)-resistant plasmid for PINK1.
Moreover, stable or transient overexpression of wild-type PINK1 increased
mitochondrial interconnectivity and suppressed toxin-induced
autophagy/mitophagy. Mitochondrial oxidant production played an essential role
in triggering mitochondrial fragmentation and autophagy in PINK1 shRNA lines.
Autophagy/mitophagy served a protective role in limiting cell death, and
overexpressing Parkin further enhanced this protective mitophagic response.
The dominant negative Drp1 mutant inhibited both fission and mitophagy in
PINK1-deficient cells. Interestingly, RNAi knockdown of autophagy proteins
Atg7 and LC3/Atg8 also decreased mitochondrial fragmentation without affecting
oxidative stress, suggesting active involvement of autophagy in morphologic
remodeling of mitochondria for clearance. To summarize, loss of PINK1 function
elicits oxidative stress and mitochondrial turnover coordinated by the
autophagic and fission/fusion machineries. Furthermore, PINK1 and Parkin may
cooperate through different mechanisms to maintain mitochondrial
homeostasis.Parkinson disease is an age-related neurodegenerative disease that affects
∼1% of the population worldwide. The causes of sporadic cases are unknown,
although mitochondrial or oxidative toxins such as
1-methyl-4-phenylpyridinium, 6-hydroxydopamine
(6-OHDA),3 and
rotenone reproduce features of the disease in animal and cell culture models
(1). Abnormalities in
mitochondrial respiration and increased oxidative stress are observed in cells
and tissues from parkinsonian patients
(2,
3), which also exhibit
increased mitochondrial autophagy
(4). Furthermore, mutations in
parkinsonian genes affect oxidative stress response pathways and mitochondrial
homeostasis (5). Thus,
disruption of mitochondrial homeostasis represents a major factor implicated
in the pathogenesis of sporadic and inherited parkinsonian disorders (PD).The PARK6 locus involved in autosomal recessive and early-onset PD
encodes for PTEN-induced kinase 1 (PINK1)
(6,
7). PINK1 is a cytosolic and
mitochondrially localized 581-amino acid serine/threonine kinase that
possesses an N-terminal mitochondrial targeting sequence
(6,
8). The primary sequence also
includes a putative transmembrane domain important for orientation of the
PINK1 domain (8), a conserved
kinase domain homologous to calcium calmodulin kinases, and a C-terminal
domain that regulates autophosphorylation activity
(9,
10). Overexpression of
wild-type PINK1, but not its PD-associated mutants, protects against several
toxic insults in neuronal cells
(6,
11,
12). Mitochondrial targeting
is necessary for some (13) but
not all of the neuroprotective effects of PINK1
(14), implicating involvement
of cytoplasmic targets that modulate mitochondrial pathobiology
(8). PINK1 catalytic activity
is necessary for its neuroprotective role, because a kinase-deficient K219M
substitution in the ATP binding pocket of PINK1 abrogates its ability to
protect neurons (14). Although
PINK1 mutations do not seem to impair mitochondrial targeting, PD-associated
mutations differentially destabilize the protein, resulting in loss of
neuroprotective activities
(13,
15).Recent studies indicate that PINK1 and Parkin interact genetically
(3,
16-18)
to prevent oxidative stress
(19,
20) and regulate mitochondrial
morphology (21). Primary cells
derived from PINK1 mutant patients exhibit mitochondrial fragmentation with
disorganized cristae, recapitulated by RNA interference studies in HeLa cells
(3).Mitochondria are degraded by macroautophagy, a process involving
sequestration of cytoplasmic cargo into membranous autophagic vacuoles (AVs)
for delivery to lysosomes (22,
23). Interestingly,
mitochondrial fission accompanies autophagic neurodegeneration elicited by the
PD neurotoxin 6-OHDA (24,
25). Moreover, mitochondrial
fragmentation and increased autophagy are observed in neurodegenerative
diseases including Alzheimer and Parkinson diseases
(4,
26-28).
Although inclusion of mitochondria in autophagosomes was once believed to be a
random process, as observed during starvation, studies involving hypoxia,
mitochondrial damage, apoptotic stimuli, or limiting amounts of aerobic
substrates in facultative anaerobes support the concept of selective
mitochondrial autophagy (mitophagy)
(29,
30). In particular,
mitochondrially localized kinases may play an important role in models
involving oxidative mitochondrial injury
(25,
31,
32).Autophagy is involved in the clearance of protein aggregates
(33-35)
and normal regulation of axonal-synaptic morphology
(36). Chronic disruption of
lysosomal function results in accumulation of subtly impaired mitochondria
with decreased calcium buffering capacity
(37), implicating an important
role for autophagy in mitochondrial homeostasis
(37,
38). Recently, Parkin, which
complements the effects of PINK1 deficiency on mitochondrial morphology
(3), was found to promote
autophagy of depolarized mitochondria
(39). Conversely, Beclin
1-independent autophagy/mitophagy contributes to cell death elicited by the PD
toxins 1-methyl-4-phenylpyridinium and 6-OHDA
(25,
28,
31,
32), causing neurite
retraction in cells expressing a PD-linked mutation in leucine-rich repeat
kinase 2 (40). Whereas
properly regulated autophagy plays a homeostatic and neuroprotective role,
excessive or incomplete autophagy creates a condition of “autophagic
stress” that can contribute to neurodegeneration
(28).As mitochondrial fragmentation
(3) and increased mitochondrial
autophagy (4) have been
described in human cells or tissues of PD patients, we investigated whether or
not the engineered loss of PINK1 function could recapitulate these
observations in human neuronal cells (SH-SY5Y). Stable knockdown of endogenous
PINK1 gave rise to mitochondrial fragmentation and increased autophagy and
mitophagy, whereas stable or transient overexpression of PINK1 had the
opposite effect. Autophagy/mitophagy was dependent upon increased
mitochondrial oxidant production and activation of fission. The data indicate
that PINK1 is important for the maintenance of mitochondrial networks,
suggesting that coordinated regulation of mitochondrial dynamics and autophagy
limits cell death associated with loss of PINK1 function. 相似文献
10.
Ruqin Kou Juliano Sartoretto Thomas Michel 《The Journal of biological chemistry》2009,284(22):14734-14743
These studies explore the connections between simvastatin, Rac1, and
AMP-activated protein kinase (AMPK) pathways in cultured vascular endothelial
cells and in arterial preparations isolated from statin-treated mice. In
addition to their prominent effects on lipoprotein metabolism, statins can
regulate the small GTPase Rac1, and may also affect the phosphorylation of the
ubiquitous AMPK. We explored pathways of statin-modulated Rac1 and AMPK
activation both in arterial preparations from statin-treated mice as well as
in cultured endothelial cells. We treated adult mice with simvastatin daily
for 2 weeks and then harvested and analyzed arterial preparations. Simvastatin
treatment of mice led to a significant increase in AMPK and LKB1
phosphorylation and to a decrease in protein kinase A activity relative to
control animals, associated with a marked increase in Rac1 activation.
Exposure of bovine aortic endothelial cells to simvastatin for 24 h strikingly
increased GTP-bound Rac1 and led to increased phosphorylation of AMPK as well
as the AMPK kinase LKB1. These responses to simvastatin were blocked by
mevalonate or geranylgeranyl pyrophosphate but not by farnesyl pyrophosphate.
Small interfering RNA (siRNA)-mediated knockdown of AMPK abrogated
simvastatin-induced Rac1 activation and LKB1 phosphorylation. Importantly,
siRNA-mediated knockdown of the key AMPK kinase, calcium/calmodulin-dependent
protein kinase kinase β, completely blocked simvastatin-induced
endothelial cell migration and also abrogated statin-promoted phosphorylation
of AMPK and LKB1, as did pharmacological inhibition with the specific
calcium/calmodulin-dependent protein kinase β inhibitor STO-609.
Moreover, siRNA-mediated knockdown of Rac1 completely blocked
simvastatin-induced LKB1 phosphorylation, but without affecting
simvastatin-induced AMPK phosphorylation. These findings establish a key role
for simvastatin in activation of a novel Rac1-dependent signaling pathway in
the vascular wall.HMG-CoA2 reductase
inhibitors, commonly known as statins, are widely prescribed for the
prevention and treatment of hypercholesterolemia and cardiovascular diseases
(1,
2). The salutary clinical
effects of these drugs derive in part from their effects on the levels of
serum lipoproteins, yet other statin responses appear to be mediated by
alterations in vascular function involving the endothelial isoform of
nitric-oxide synthase (3) and
related signaling pathways. Inhibition of HMG-CoA reductase suppresses the
cellular levels of its enzymatic product mevalonate, thereby attenuating
formation both of cholesterol as well as the synthesis of distinct isoprenoid
compounds such as farnesyl pyrophosphate (Fpp) and geranylgeranyl
pyrophosphate (GGpp). Many key signaling proteins are covalently modified by
these isoprenoids, which are the products of a metabolic pathway that diverges
from the pathway that leads to cholesterol synthesis downstream of HMG-CoA
reductase. These isoprenoid compounds can provide lipophilic anchors that
facilitate membrane targeting and modulate protein-protein interactions of
many key signaling proteins. One such iso-prenylated signaling protein is the
GTP-binding cytoskeletonassociated protein Rac1, a member of the Rho GTPase
small G protein family that undergoes geranylgeranylation at its C terminus.
Statins also affect post-translational modification of another small GTPase,
RhoA, that, like Rac1, is a geranylgeranylated protein that is an important
determinant of vascular signaling
(4–8).
Rac1 has particularly important roles in vascular endothelial cells, where
this cytoskeleton regulatory protein modulates activity of the endothelial
isoform of nitric-oxide synthase (eNOS), a key determinant of vascular
homeostasis (9). Rac1
activation in endothelial cells is influenced by the AMP-activated protein
kinase (AMPK) (6), which itself
is phosphorylated by the protein kinase LKB1 and by the
calcium-calmodulin-dependent protein kinase β (CaMKKβ) (see review
(10)). In recent years,
numerous reports have described effects of statins on variety of these
signaling proteins in different experimental systems
(11–14).Statins have been shown to promote the phosphorylation of AMPK
(13), a heterotrimeric enzyme
involved in the modulation of cellular energy pathways that has also been
implicated in eNOS regulation
(3,
15–17).
AMPK was originally discovered and characterized as a cellular “energy
sensor” that can be activated by increases in the intracellular AMP:ATP
ratio (18). However, in recent
years, it has become clear that AMPK is also regulated through AMP-independent
pathways involving enzyme phosphorylation on threonine 172 of the enzyme''s
α subunit, leading to marked enzyme activation
(19). Protein kinases that
phosphorylate AMPK include the tumor suppressor LKB1 and the
calcium/calmodulin-dependent kinase CaMKKβ. LKB1 itself is a
phosphoprotein. The pathways that regulate LKB1 are incompletely understood,
and a variety of upstream protein kinases have been implicated in LKB1
regulation (see review (20)).
CaMKKβ is principally regulated by calcium binding, but this kinase may
also be phosphorylated by the cAMP-dependent protein kinase PKA
(21,
22). Another substrate for PKA
in vascular cells is the actin-binding phosphoprotein VASP
(23,
24); the phosphorylation state
of VASP at its PKA site can serve as a surrogate marker for the activity of
cAMP-dependent signaling pathways in the vascular wall
(25). CaMKKβ has been
shown to be involved in AMPK regulation in endothelial cells in response to
receptor tyrosine kinase activation and via G protein-coupled receptor
pathways (6). Activated AMPK
directly phosphorylates eNOS, and this kinase thereby appears be an important
determinant of NO-dependent signaling in endothelial cells. However, much
remains to be learned about the molecular mechanisms whereby statins enhance
AMPK activation.In cultured cells, statins have been shown to inhibit the
geranylgeranylation of Rac1, associated with an increase in Rac1 GTP binding
and activation (26). The
activation of Rac1 is a key step in eNOS activation: siRNA-mediated Rac1
“knockdown” in endothelial cells markedly suppresses receptor
signaling to eNOS (5,
7). siRNA-mediated AMPK
knockdown suppresses Rac1 activation, again leading to the attenuation of
receptor-dependent activation of eNOS
(6). The relationships among
these various statin-modulated signaling pathways are incompletely
characterized. The present studies identify CaMKKβ and LKB1 as critical
determinants of simvastatin-dependent activation of AMPK- and Rac1-modulated
signaling and reveal that Rac1 in turn regulates LKB1 phosphorylation. 相似文献
11.
Siying Wang Wen-Mei Yu Wanming Zhang Keith R. McCrae Benjamin G. Neel Cheng-Kui Qu 《The Journal of biological chemistry》2009,284(2):913-920
Mutations in SHP-2 phosphatase (PTPN11) that cause hyperactivation
of its catalytic activity have been identified in Noonan syndrome and various
childhood leukemias. Recent studies suggest that the gain-of-function (GOF)
mutations of SHP-2 play a causal role in the pathogenesis of these diseases.
However, the molecular mechanisms by which GOF mutations of SHP-2 induce these
phenotypes are not fully understood. Here, we show that GOF mutations in
SHP-2, such as E76K and D61G, drastically increase spreading and migration of
various cell types, including hematopoietic cells, endothelial cells, and
fibroblasts. More importantly, in vivo angiogenesis in SHP-2 D61G
knock-in mice is also enhanced. Mechanistic studies suggest that the increased
cell migration is attributed to the enhanced β1 integrin outside-in
signaling. In response to β1 integrin cross-linking or fibronectin
stimulation, activation of ERK and Akt kinases is greatly increased by SHP-2
GOF mutations. Also, integrin-induced activation of RhoA and Rac1 GTPases is
elevated. Interestingly, mutant cells with the SHP-2 GOF mutation (D61G) are
more sensitive than wild-type cells to the suppression of cell motility by
inhibition of these pathways. Collectively, these studies reaffirm the
positive role of SHP-2 phosphatase in cell motility and suggest a new
mechanism by which SHP-2 GOF mutations contribute to diseases.SHP-2, a multifunctional SH2 domain-containing protein-tyrosine phosphatase
implicated in diverse cell signaling processes
(1–3),
plays a critical role in cellular function. Homozygous deletion of Exon
2 (4) or Exon 3
(5) of the SHP-2 gene
(PTPN11) in mice leads to early embryonic lethality prior to and at
midgestation, respectively. SHP-2 null mutant mice die much earlier, at
peri-implantation (4). Exon
3 deletion mutation of SHP-2 blocks hematopoietic potential of embryonic
stem cells both in vitro and in vivo
(6–8),
whereas SHP-2 null mutation causes inner cell mass death and diminished
trophoblast stem cell survival
(4). Recent studies on SHP-2
conditional knock-out or tissue-specific knock-out mice have further revealed
an array of important functions of this phosphatase in various physiological
processes
(9–12).
The phenotypes demonstrated by loss of SHP-2 function are apparently
attributed to the role of SHP-2 in the cell signaling pathways induced by
growth factors/cytokines. SHP-2 generally promotes signal transmission in
growth factor/cytokine signaling in both catalytic-dependent and -independent
fashion
(1–3).
The positive role of SHP-2 in the intracellular signaling processes, in
particular, the ERK3
and PI3K/Akt kinase pathways, has been well established, although the
underlying mechanism remains elusive, in particular, the signaling function of
the catalytic activity of SHP-2 in these pathways is poorly understood.In addition to the role of SHP-2 in cell proliferation and differentiation,
the phenotypes induced by loss of SHP-2 function may be associated with its
role in cell migration. Indeed, dominant negative SHP-2 disrupts
Xenopus gastrulation, causing tail truncations
(13,
14). Targeted Exon 3
deletion mutation in SHP-2 results in decreased cell spreading, migration
(15,
16), and impaired limb
development in the chimeric mice
(7). The role of SHP-2 in cell
adhesion and migration has also been demonstrated by catalytically inactive
mutant SHP-2-overexpressing cells
(17–20).
The molecular mechanisms by which SHP-2 regulates these cellular processes,
however, have not been well defined. For example, the role of SHP-2 in the
activation of the Rho family small GTPases that is critical for cell motility
is still controversial. Both positive
(19,
21,
22) and negative roles
(18,
23) for SHP-2 in this context
have been reported. Part of the reason for this discrepancy might be due to
the difference in the cell models used. Catalytically inactive mutant SHP-2
was often used to determine the role of SHP-2 in cell signaling. In the
catalytically inactive mutant SHP-2-overexpressing cells, the catalytic
activity of endogenous SHP-2 is inhibited. However, as SHP-2 also functions
independent of its catalytic activity, overexpression of catalytically
deficient SHP-2 may also increase its scaffolding function, generating complex
effects.The critical role of SHP-2 in cellular function is further underscored by
the identification of SHP-2 mutations in human diseases. Genetic lesions in
PTPN11 that cause hyperactivation of SHP-2 catalytic activity have
been identified in the developmental disorder Noonan syndrome
(24) and various childhood
leukemias, including juvenile myelomonocytic leukemia (JMML), B cell acute
lymphoblastic leukemia, and acute myeloid leukemia
(25,
26). In addition, activating
mutations in SHP-2 have been identified in sporadic solid tumors
(27). The SHP-2 mutations
appear to play a causal role in the development of these diseases as SHP-2
mutations and other JMML-associated Ras or Neurofibromatosis 1 mutations are
mutually exclusive in the patients
(24–27).
Moreover, single SHP-2 gain-of-function (GOF) mutations are sufficient to
induce Noonan syndrome, cytokine hypersensitivity in hematopoietic progenitor
cells, and JMML-like myeloproliferative disease in mice
(28–32).
Gain-of-function cell models derived from the newly available SHP-2 GOF
mutation (D61G) knock-in mice
(28) now provide us with a
good opportunity to clarify the role of SHP-2 in cell motility. Unlike the
dominant negative approach in which overexpression of mutant forms of SHP-2
generates complex effects, the SHP-2 D61G knock-in model eliminates this
possibility as the mutant SHP-2 is expressed at the physiological level
(28). Additionally, defining
signaling functions of GOF mutant SHP-2 in cell movement can also help
elucidate the molecular mechanisms by which SHP-2 mutations contribute to the
relevant diseases. 相似文献
12.
As obligate intracellular parasites, viruses exploit diverse cellular
signaling machineries, including the mitogen-activated protein-kinase pathway,
during their infections. We have demonstrated previously that the open reading
frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus interacts with p90
ribosomal S6 kinases (RSKs) and strongly stimulates their kinase activities
(Kuang, E., Tang, Q., Maul, G. G., and Zhu, F.
(2008) J. Virol. 82
,1838
-1850). Here, we define the
mechanism by which ORF45 activates RSKs. We demonstrated that binding of ORF45
to RSK increases the association of extracellular signal-regulated kinase
(ERK) with RSK, such that ORF45, RSK, and ERK formed high molecular mass
protein complexes. We further demonstrated that the complexes shielded active
pERK and pRSK from dephosphorylation. As a result, the complex-associated RSK
and ERK were activated and sustained at high levels. Finally, we provide
evidence that this mechanism contributes to the sustained activation of ERK
and RSK in Kaposi sarcoma-associated herpesvirus lytic replication.The extracellular signal-regulated kinase
(ERK)2
mitogen-activated protein kinase (MAPK) signaling pathway has been implicated
in diverse cellular physiological processes including proliferation, survival,
growth, differentiation, and motility
(1-4)
and is also exploited by a variety of viruses such as Kaposi
sarcoma-associated herpesvirus (KSHV), human cytomegalovirus, human
immunodeficiency virus, respiratory syncytial virus, hepatitis B virus,
coxsackie, vaccinia, coronavirus, and influenza virus
(5-17).
The MAPK kinases relay the extracellular signaling through sequential
phosphorylation to an array of cytoplasmic and nuclear substrates to elicit
specific responses (1,
2,
18). Phosphorylation of MAPK
is reversible. The kinetics of deactivation or duration of signaling dictates
diverse biological outcomes
(19,
20). For example, sustained
but not transient activation of ERK signaling induces the differentiation of
PC12 cells into sympathetic-like neurons and transformation of NIH3T3 cells
(20-22).
During viral infection, a unique biphasic ERK activation has been observed for
some viruses (an early transient activation triggered by viral binding or
entry and a late sustained activation correlated with viral gene expression),
but the responsible viral factors and underlying mechanism for the sustained
ERK activation remain largely unknown
(5,
8,
13,
23).The p90 ribosomal S6 kinases (RSKs) are a family of serine/threonine
kinases that lie at the terminus of the ERK pathway
(1,
24-26).
In mammals, four isoforms are known, RSK1 to RSK4. Each one has two
catalytically functional kinase domains, the N-terminal kinase domain (NTKD)
and C-terminal kinase domain (CTKD) as well as a linker region between the
two. The NTKD is responsible for phosphorylation of exogenous substrates, and
the CTKD and linker region regulate RSK activation
(1,
24,
25). In quiescent cells ERK
binds to the docking site in the C terminus of RSK
(27-29).
Upon mitogen stimulation, ERK is activated by its upstream MAPK/ERK kinase
(MEK). The active ERK phosphorylates Thr-359/Ser-363 of RSK in the linker
region (amino acid numbers refer to human RSK1) and Thr-573 in the CTKD
activation loop. The activated CTKD then phosphorylates Ser-380 in the linker
region, creating a docking site for 3-phosphoinositide-dependent protein
kinase-1. The 3-phosphoinositide-dependent protein kinase-1 phosphorylates
Ser-221 of RSK in the activation loop and activates the NTKD. The activated
NTKD autophosphorylates the serine residue near the ERK docking site, causing
a transient dissociation of active ERK from RSK
(25,
26,
28). The stimulation of
quiescent cells by a mitogen such as epidermal growth factor or a phorbol
ester such as 12-O-tetradecanoylphorbol-13-acetate (TPA) usually
results in a transient RSK activation that lasts less than 30 min. RSKs have
been implicated in regulating cell survival, growth, and proliferation.
Mutation or aberrant expression of RSK has been implicated in several human
diseases including Coffin-Lowry syndrome and prostate and breast cancers
(1,
24,
25,
30-32).KSHV is a human DNA tumor virus etiologically linked to Kaposi sarcoma,
primary effusion lymphoma, and a subset of multicentric Castleman disease
(33,
34). Infection and
reactivation of KSHV activate multiple MAPK pathways
(6,
12,
35). Noticeably, the ERK/RSK
activation is sustained late during KSHV primary infection and reactivation
from latency (5,
6,
12,
23), but the mechanism of the
sustained ERK/RSK activation is unclear. Recently, we demonstrated that ORF45,
an immediate early and also virion tegument protein of KSHV, interacts with
RSK1 and RSK2 and strongly stimulates their kinase activities
(23). We also demonstrated
that the activation of RSK plays an essential role in KSHV lytic replication
(23). In the present study we
determined the mechanism of ORF45-induced sustained ERK/RSK activation. We
found that ORF45 increases the association of RSK with ERK and protects them
from dephosphorylation, causing sustained activation of both ERK and RSK. 相似文献
13.
John W. Hardin Francis E. Reyes Robert T. Batey 《The Journal of biological chemistry》2009,284(22):15317-15324
In archaea and eukarya, box C/D ribonucleoprotein (RNP) complexes are
responsible for 2′-O-methylation of tRNAs and rRNAs. The
archaeal box C/D small RNP complex requires a small RNA component (sRNA)
possessing Watson-Crick complementarity to the target RNA along with three
proteins: L7Ae, Nop5p, and fibrillarin. Transfer of a methyl group from
S-adenosylmethionine to the target RNA is performed by fibrillarin,
which by itself has no affinity for the sRNA-target duplex. Instead, it is
targeted to the site of methylation through association with Nop5p, which in
turn binds to the L7Ae-sRNA complex. To understand how Nop5p serves as a
bridge between the targeting and catalytic functions of the box C/D small RNP
complex, we have employed alanine scanning to evaluate the interaction between
the Pyrococcus horikoshii Nop5p domain and an L7Ae box C/D RNA
complex. From these data, we were able to construct an isolated RNA-binding
domain (Nop-RBD) that folds correctly as demonstrated by x-ray crystallography
and binds to the L7Ae box C/D RNA complex with near wild type affinity. These
data demonstrate that the Nop-RBD is an autonomously folding and functional
module important for protein assembly in a number of complexes centered on the
L7Ae-kinkturn RNP.Many biological RNAs require extensive modification to attain full
functionality in the cell (1).
Currently there are over 100 known RNA modification types ranging from small
functional group substitutions to the addition of large multi-cyclic ring
structures (2). Transfer RNA,
one of many functional RNAs targeted for modification
(3-6),
possesses the greatest modification type diversity, many of which are
important for proper biological function
(7). Ribosomal RNA, on the
other hand, contains predominantly two types of modified nucleotides:
pseudouridine and 2′-O-methylribose
(8). The crystal structures of
the ribosome suggest that these modifications are important for proper folding
(9,
10) and structural
stabilization (11) in
vivo as evidenced by their strong tendency to localize to regions
associated with function (8,
12,
13). These roles have been
verified biochemically in a number of cases
(14), whereas newly emerging
functional modifications are continually being investigated.Box C/D ribonucleoprotein
(RNP)3 complexes serve
as RNA-guided site-specific 2′-O-methyltransferases in both
archaea and eukaryotes (15,
16) where they are referred to
as small RNP complexes and small nucleolar RNPs, respectively. Target RNA
pairs with the sRNA guide sequence and is methylated at the 2′-hydroxyl
group of the nucleotide five bases upstream of either the D or D′ box
motif of the sRNA (Fig. 1,
star) (17,
18). In archaea, the internal
C′ and D′ motifs generally conform to a box C/D consensus sequence
(19), and each sRNA contains
two guide regions ∼12 nucleotides in length
(20). The bipartite
architecture of the RNP potentially enables the complex to methylate two
distinct RNA targets (21) and
has been shown to be essential for site-specific methylation
(22).Open in a separate windowFIGURE 1.Organization of the archaeal box C/D complex. The protein components
of this RNP are L7Ae, Nop5p, and fibrillarin, which together bind a box C/D
sRNA. The regions of the Box C/D sRNA corresponding to the conserved C, D,
C′, and D′ boxes are labeled. The target RNA binds the sRNA
through Watson-Crick pairing and is methylated by fibrillarin at the fifth
nucleotide from the D/D′ boxes (star).In addition to the sRNA, the archaeal box C/D complex requires three
proteins for activity (23):
the ribosomal protein L7Ae
(24,
25), fibrillarin, and the
Nop56/Nop58 homolog Nop5p (Fig.
1). L7Ae binds to both box C/D and the C′/D′ motifs
(26), which respectively
comprise kink-turn (27) or
k-loop structures (28), to
initiate the assembly of the RNP
(29,
30). Fibrillarin performs the
methyl group transfer from the cofactor S-adenosylmethionine to the
target RNA
(31-33).
For this to occur, the active site of fibrillarin must be positioned precisely
over the specific 2′-hydroxyl group to be methylated. Although
fibrillarin methylates this functional group in the context of a Watson-Crick
base-paired helix (guide/target), it has little to no binding affinity for
double-stranded RNA or for the L7Ae-sRNA complex
(22,
26,
33,
34). Nop5p serves as an
intermediary protein bringing fibrillarin to the complex through its
association with both the L7Ae-sRNA complex and fibrillarin
(22). Along with its role as
an intermediary between fibrillarin and the L7Ae-sRNA complex, Nop5p possesses
other functions not yet fully understood. For example, Nop5p self-dimerizes
through a coiled-coil domain
(35) that in most archaea and
eukaryotic homologs includes a small insertion sequence of unknown function
(36,
37). However, dimerization and
fibrillarin binding have been shown to be mutually exclusive in
Methanocaldococcus jannaschii Nop5p, potentially because of the
presence of this insertion sequence
(36). Thus, whether Nop5p is a
monomer or a dimer in the active RNP is still under debate.In this study, we focus our attention on the Nop5p protein to investigate
its interaction with a L7Ae box C/D RNA complex because both the
fibrillarin-Nop5p and the L7Ae box C/D RNA interfaces are known from crystal
structures (29,
35,
38). Individual residues on
the surface of a monomeric form of Nop5p (referred to as mNop5p)
(22) were mutated to alanine,
and the effect on binding affinity for a L7Ae box C/D motif RNA complex was
assessed through the use of electrophoretic mobility shift assays. These data
reveal that residues important for binding cluster within the highly conserved
NOP domain (39,
40). To demonstrate that this
domain is solely responsible for the affinity of Nop5p for the preassembled
L7Ae box C/D RNA complex, we expressed and purified it in isolation from the
full Nop5p protein. The isolated Nop-RBD domain binds to the L7Ae box C/D RNA
complex with nearly wild type affinity, demonstrating that the Nop-RBD is
truly an autonomously folding and functional module. Comparison of our data
with the crystal structure of the homologous spliceosomal hPrp31-15.5K
protein-U4 snRNA complex (41)
suggests the adoption of a similar mode of binding, further supporting a
crucial role for the NOP domain in RNP complex assembly. 相似文献
14.
Ho-Sup Lee Chinten James Lim Wilma Puzon-McLaughlin Sanford J. Shattil Mark H. Ginsberg 《The Journal of biological chemistry》2009,284(8):5119-5127
Rap1 small GTPases interact with Rap1-GTP-interacting adaptor molecule
(RIAM), a member of the MRL (Mig-10/RIAM/Lamellipodin) protein family, to
promote talin-dependent integrin activation. Here, we show that MRL proteins
function as scaffolds that connect the membrane targeting sequences in Ras
GTPases to talin, thereby recruiting talin to the plasma membrane and
activating integrins. The MRL proteins bound directly to talin via short,
N-terminal sequences predicted to form amphipathic helices. RIAM-induced
integrin activation required both its capacity to bind to Rap1 and to talin.
Moreover, we constructed a minimized 50-residue Rap-RIAM module containing the
talin binding site of RIAM joined to the membrane-targeting sequence of Rap1A.
This minimized Rap-RIAM module was sufficient to target talin to the plasma
membrane and to mediate integrin activation, even in the absence of Rap1
activity. We identified a short talin binding sequence in Lamellipodin (Lpd),
another MRL protein; talin binding Lpd sequence joined to a Rap1
membrane-targeting sequence is sufficient to recruit talin and activate
integrins. These data establish the mechanism whereby MRL proteins interact
with both talin and Ras GTPases to activate integrins.Increased affinity (“activation”) of cellular integrins is
central to physiological events such as cell migration, assembly of the
extracellular matrix, the immune response, and hemostasis
(1). Each integrin comprises a
type I transmembrane α and β subunit, each of which has a large
extracellular domain, a single transmembrane domain, and a cytoplasmic domain
(tail). Talin binds to most integrin β cytoplasmic domains and the
binding of talin to the integrin β tail initiates integrin activation
(2–4).
A small, PTB-like domain of talin mediates activation via a two-site
interaction with integrin β tails
(5), and this PTB domain is
functionally masked in the intact talin molecule
(6). A central question in
integrin biology is how the talin-integrin interaction is regulated to control
integrin activation; recent work has implicated Ras GTPases as critical
signaling modules in this process
(7).Ras proteins are small monomeric GTPases that cycle between the GTP-bound
active form and the GDP-bound inactive form. Guanine nucleotide exchange
factors (GEFs) promote Ras activity by exchanging bound GDP for GTP, whereas
GTPase-activating proteins
(GAPs)3 enhance the
hydrolysis of Ras-bound GTP to GDP (for review, see Ref.
8). The Ras subfamily members
Rap1A and Rap1B stimulate integrin activation
(9,
10). For example, expression
of constitutively active Rap1 activates integrin αMβ2 in
macrophage, and inhibition of Rap1 abrogated integrin activation induced by
inflammatory agonists
(11–13).
Murine T-cells expressing constitutively active Rap1 manifest enhanced
integrin dependent cell adhesion
(14). In platelets, Rap1 is
rapidly activated by platelet agonists
(15,
16). A knock-out of Rap1B
(17) or of the Rap1GEF,
RasGRP2 (18), resulted in
impairment of αIIbβ3-dependent platelet aggregation, highlighting
the importance of Rap1 in platelet aggregation in vivo. Thus, Rap1
GTPases play important roles in the activation of several integrins in
multiple biological contexts.Several Rap1 effectors have been implicated in integrin activation
(19–21).
Rap1-GTP-interacting adaptor molecule (RIAM) is a Rap1 effector that is a
member of the MRL (Mig-10/RIAM/Lamellipodin) family of adaptor proteins
(20). RIAM contains Ras
association (RA) and pleckstrin homology (PH) domains and proline-rich
regions, which are defining features of the MRL protein family. In Jurkat
cells, RIAM overexpression induces β1 and β2 integrin-mediated cell
adhesion, and RIAM knockdown abolishes Rap1-dependent cell adhesion
(20), indicating RIAM is a
downstream regulator of Rap1-dependent signaling. RIAM regulates actin
dynamics as RIAM expression induces cell spreading; conversely, its depletion
reduces cellular F-actin content
(20). Whereas RIAM is greatly
enriched in hematopoietic cells, Lamellipodin (Lpd) is a paralogue present in
fibroblasts and other somatic cells
(22).Recently we used forward, reverse, and synthetic genetics to engineer and
order an integrin activation pathway in Chinese hamster ovary cells expressing
a prototype activable integrin, platelet αIIbβ3. We found that Rap1
induced formation of an “integrin activation complex” containing
RIAM and talin (23). Here, we
have established the mechanism whereby Ras GTPases cooperate with MRL family
proteins, RIAM and Lpd, to regulate integrin activation. We find that MRL
proteins function as scaffolds that connect the membrane targeting sequences
in Ras GTPases to talin, thereby recruiting talin to integrins at the plasma
membrane. 相似文献
15.
Jonathan M. Budzik So-Young Oh Olaf Schneewind 《The Journal of biological chemistry》2009,284(19):12989-12997
Bacillus cereus and other Gram-positive bacteria elaborate pili
via a sortase D-catalyzed transpeptidation mechanism from major and minor
pilin precursor substrates. After cleavage of the LPXTG sorting
signal of the major pilin, BcpA, sortase D forms an amide bond between the
C-terminal threonine and the amino group of lysine within the YPKN motif of
another BcpA subunit. Pilus assembly terminates upon sortase A cleavage of the
BcpA sorting signal, resulting in a covalent bond between BcpA and the cell
wall cross-bridge. Here, we show that the IPNTG sorting signal of BcpB, the
minor pilin, is cleaved by sortase D but not by sortase A. The C-terminal
threonine of BcpB is amide-linked to the YPKN motif of BcpA, thereby
positioning BcpB at the tip of pili. Thus, unique attributes of the sorting
signals of minor pilins provide Gram-positive bacteria with a universal
mechanism ordering assembly of pili.Sortases catalyze transpeptidation reactions to assemble proteins in the
envelope of Gram-positive bacteria
(1). Secreted proteins require
a C-terminal sorting signal for sortase recognition such that sortase cleaves
the substrate at a short peptide motif and forms a thioester-linked
intermediate to its active site cysteine
(2–4).
Nucleophilic attack by an amino group within the bacterial envelope resolves
the thioester intermediate, generating an amide bond tethering surface
proteins at their C terminus onto Gram-positive bacteria
(5). Four classes of sortases
can be distinguished on the basis of sequence homology and substrate
recognition (6,
7). Sortase A cleaves secreted
protein at LPXTG sorting signals and recognizes the amino group of
lipid II peptidoglycan precursors as a nucleophile
(8,
9). Sortase B cleaves protein
substrates at NPQTN sorting signals
(10). This enzyme immobilizes
proteins within fully assembled cell walls, utilizing the cell wall
cross-bridge as a nucleophile
(11). Sortase C cuts LPNTA
sorting signals and anchors proteins to the peptidoglycan cross-bridges in
sporulating bacteria (12,
13). Finally, sortase D
catalyzes transpeptidation reactions in the assembly of pili
(14,
15). Sortase D recognizes the
amino group of lysine residues within the YPKN motif of pilin subunits as
nucleophiles (16). The
resultant sortase D-catalyzed amide bond links adjacent pilin subunits to grow
the pilus fiber (16,
17).Pili of Gram-positive bacteria comprised either two or three different
pilin subunits synthesized as cytoplasmic precursors with N-terminal signal
peptides and C-terminal sorting signals (P1 precursors)
(14,
18). After translocation
across the plasma membrane, P2 precursor species arise from removal of the
signal peptide from P1 precursors by a signal peptidase
(16). Bacillus cereus
pili are composed of two subunits; that is, the major pilin, BcpA, and the
minor pilin, BcpB (15). In
contrast to BcpA, which is deposited throughout the pilus, BcpB is found at
fiber tip (15). Sortase D
cleaves the BcpA LPXTG motif sorting signal between the threonine and
glycine residues to form an amide bond to the ε-amino group of the lysine
within the YPKN motif of adjacent BcpA subunits
(16). However, sortase A also
cleaves BcpA precursors, which are subsequently linked to the side chain amino
group of meso-diaminopimelic acid within lipid II
(19). The latter reaction
serves to terminate fiber elongation, immobilizing BcpA pili in the cell wall
envelope (19).The conservation of sortase D, the YPKN motif, and C-terminal sorting
signal in major pilin subunits suggest a universal pilus assembly mechanism
among Gram-positive bacteria
(14,
20). However, the molecular
mechanism whereby bacilli deposit BcpB, the minor pilin, at the tip of BcpA
pili is not known. Although the BcpB precursor harbors an N-terminal signal
peptide and a C-terminal IPNTG sorting signal, it lacks the YPKN pilin motif
of the major subunit (15).
Furthermore, the substrate properties of the BcpB IPNTG sorting signal for the
four classes of sortases expressed by bacilli has yet to be established. 相似文献
16.
John Brognard Matthew Niederst Gloria Reyes Noel Warfel Alexandra C. Newton 《The Journal of biological chemistry》2009,284(22):15215-15223
PHLPP2 (PH domain leucine-rich repeat protein phosphatase 2) terminates Akt
and protein kinase C (PKC) activity by specifically dephosphorylating these
kinases at a key regulatory site, the hydrophobic motif (Ser-473 in Akt1).
Here we identify a polymorphism that results in an amino acid change from a
Leu to Ser at codon 1016 in the phosphatase domain of PHLPP2, which reduces
phosphatase activity toward Akt both in vitro and in cells, in turn
resulting in reduced apoptosis. Depletion of endogenous PHLPP2 variants in
breast cancer cells revealed the Ser-1016 variant is less functional toward
both Akt and PKC. In pair-matched high grade breast cancer samples we observed
retention of only the Ser allele from heterozygous patients (identical results
were observed in a pair-matched normal and tumor cell line). Thus, we have
identified a functional polymorphism that impairs the activity of PHLPP2 and
correlates with elevated Akt phosphorylation and increased PKC levels.Breast cancer is diagnosed in ∼180,000 women and is the cause of 40,000
deaths each year in the
U.S.2 A prevalent
underlying mechanism driving tumorigenesis is aberrant signal transduction
pathways that result in constitutive activation of cell growth, proliferation,
and survival pathways (2). A
well characterized signal transduction pathway in breast cancer that promotes
cellular survival, growth, and proliferation is the phosphatidylinositol
3-kinase/Akt pathway (3). This
pathway is activated by a number of mechanisms, including gene amplification
or gain of function mutations in upstream receptor protein-tyrosine kinases
(4,
5), constitutive activation of
hormone receptors (6),
activating mutations in phosphatidylinositol 3-kinase and Akt
(7,
8), and loss of function
mutations in the regulatory phosphatase
PTEN3 (phosphatase and
tensin homolog on chromosome ten)
(9). Thus, Akt is a major
regulator of breast tumorigenesis.There are three isoforms of Akt present in humans. All three isoforms
contain activating phosphorylation sites in the activation loop (Thr-308 in
Akt1) and in the C-terminal hydrophobic motif (Ser-473 in Akt1)
(10). Upon growth factor
receptor stimulation, phosphatidylinositol 3-kinase becomes activated and
phosphorylates the D3 position of, typically, phosphatidylinositol
(4,
5) bisphosphate to generate
phosphatidylinositol (3,4,5)-trisphosphate
(11). This
3′-phosphorylated lipid recruits Akt to the plasma membrane by binding
to its PH domain, resulting in conformational changes that allow access to the
activation loop phosphorylation site
(11). Constitutively bound
phosphatidylinositol-dependent kinase-1 then phosphorylates Akt at Thr-308,
accompanied by phosphorylation at Ser-473 resulting in a catalytically active
kinase (12). Phosphorylation
of Ser-473 depends on the mTORC2 complex
(13-16).
Signaling through this pathway is terminated by removal of the lipid second
messenger phosphatidylinositol (3,4,5)-trisphosphate catalyzed by the
phosphatase PTEN and by direct dephosphorylation of Akt by the
recently-identified PHLPP family of phosphatases and protein phosphatase
2A-type phosphatases
(17-20).The PHLPP family of phosphatases comprise three variants, the alternatively
spliced PHLPP1α and PHLPP1β, and PHLPP2
(21). PHLPP1 and PHLPP2
specifically dephosphorylate the hydrophobic motif of specific Akt isozymes,
thus decreasing Akt activity and promoting apoptosis
(18,
19). PHLPP2 binds and
dephosphorylates Akt1 and Akt3, whereas PHLPP1 binds and dephosphorylates Akt2
and Akt3 (18,
22). Their role in
inactivating Akt suggests that both PHLPP1 and PHLPP2 could be potential tumor
suppressors. Consistent with such a role, these phosphatases also
dephosphorylate the hydrophobic motif of PKC, resulting in degradation of PKC.
For this kinase, phosphorylation stabilizes the enzyme, so that the effect of
depletion of the PHLPP phosphatases is to increase PKC protein levels
(23). PKC is a well
characterized oncogene, and loss of function of the PHLPP phosphatases could
increase PKC protein levels and promote tumorigenesis
(24). Providing further
rationale that PHLPP2 could be a potential tumor suppressor, the phosphatase
is located on chromosome 16q22.3, a region that encounters frequent loss of
heterozygosity (LOH) in many primary and malignant breast tumors
(25).Here we identify a non-synonymous polymorphism that results in an amino
acid change from a Leu to a Ser at codon 1016 in the PP2C phosphatase domain
of PHLPP2. Overexpression studies reveal the Ser-1016 variant has impaired
phosphatase activity and is less effective at inducing apoptosis than the
Leu-1016 variant. When comparing a pair-matched normal and breast cancer cell
line or pair-matched normal and high grade tumor patient samples that are
heterozygous, we observe preferential loss of the Leu allele in the tumor
tissue or breast cancer cell line. This observation provides evidence that
PHLPP2 could be one of the elusive tumor suppressor genes on chromosome 16q,
and for heterozygous patients, loss of the more catalytically active Leu-1016
may promote breast tumorigenesis. 相似文献
17.
Eva Brombacher Simon Urwyler Curdin Ragaz Stefan S. Weber Keiichiro Kami Michael Overduin Hubert Hilbi 《The Journal of biological chemistry》2009,284(8):4846-4856
The causative agent of Legionnaires disease, Legionella
pneumophila, forms a replicative vacuole in phagocytes by means of the
intracellular multiplication/defective organelle trafficking (Icm/Dot) type IV
secretion system and translocated effector proteins, some of which subvert
host GTP and phosphoinositide (PI) metabolism. The Icm/Dot substrate SidC
anchors to the membrane of Legionella-containing vacuoles (LCVs) by
specifically binding to phosphatidylinositol 4-phosphate (PtdIns(4)P). Using a
nonbiased screen for novel L. pneumophila PI-binding proteins, we
identified the Rab1 guanine nucleotide exchange factor (GEF) SidM/DrrA as the
predominant PtdIns(4)P-binding protein. Purified SidM specifically and
directly bound to PtdIns(4)P, whereas the SidM-interacting Icm/Dot substrate
LidA preferentially bound PtdIns(3)P but also PtdIns(4)P, and the L.
pneumophila Arf1 GEF RalF did not bind to any PIs. The PtdIns(4)P-binding
domain of SidM was mapped to the 12-kDa C-terminal sequence, termed
“P4M” (PtdIns4P binding of
SidM/DrrA). The isolated P4M domain is largely helical and
displayed higher PtdIns(4)P binding activity in the context of the
α-helical, monomeric full-length protein. SidM constructs containing P4M
were translocated by Icm/Dot-proficient L. pneumophila and localized
to the LCV membrane, indicating that SidM anchors to PtdIns(4)P on LCVs via
its P4M domain. An L. pneumophila ΔsidM mutant strain
displayed significantly higher amounts of SidC on LCVs, suggesting that SidM
and SidC compete for limiting amounts of PtdIns(4)P on the vacuole. Finally,
RNA interference revealed that PtdIns(4)P on LCVs is specifically formed by
host PtdIns 4-kinase IIIβ. Thus, L. pneumophila exploits
PtdIns(4)P produced by PtdIns 4-kinase IIIβ to anchor the effectors SidC
and SidM to LCVs.The Gram-negative pathogen Legionella pneumophila is the causative
agent of Legionnaires disease, but it evolved as a parasite of various species
of environmental predatory protozoa, including the social amoeba
Dictyostelium discoideum
(1,
2). The human disease is linked
to the inhalation of contaminated aerosols, followed by replication in
alveolar macrophages. To accommodate the transfer between host cells, L.
pneumophila alternates between replicative and transmissive phases, the
regulation of which includes an apparent quorum-sensing system
(3–5).In macrophages and amoebae, L. pneumophila forms a replicative
compartment, the Legionella-containing vacuole
(LCV).3 LCVs avoid
fusion with lysosomes (6),
intercept vesicular traffic at endoplasmic reticulum (ER) exit sites
(7), and fuse with the ER
(8–10).
The uptake of L. pneumophila and formation of LCVs in macrophages and
amoebae depends on the Icm/Dot type IV secretion system (T4SS)
(11–14).
Although more than 100 Icm/Dot substrates (“effector” proteins)
have been identified to date, only few are functionally characterized,
including effectors that interfere with host cell signal transduction, vesicle
trafficking, or apoptotic pathways
(15–18).Two Icm/Dot-translocated substrates, SidM/DrrA
(19,
20) and RalF
(21), have been characterized
as guanine nucleotide exchange factors (GEFs) for the Rho subfamily of small
GTPases. These bacterial GEFs are recruited to and activate their targets on
LCVs. Small GTPases of the Rho subfamily are involved in many eukaryotic
signal transduction pathways and in actin cytoskeleton regulation
(22). Inactive Rho GTPases
bind GDP and a guanine nucleotide dissociation inhibitor (GDI). The GTPases
are activated by removal of the GDI and the exchange of GDP with GTP by GEFs,
which promotes the interaction with downstream effector proteins, such as
protein or lipid kinases and various adaptor proteins. The cycle is closed by
hydrolysis of the bound GTP, which is mediated by GTPase-activating
proteins.SidM is a GEF for Rab1, which is essential for ER to Golgi vesicle
transport, and additionally, SidM acts as a GDI displacement factor (GDF) to
activate Rab1 (23,
24). The function of SidM is
assisted by the Icm/Dot substrate LidA, which also localizes to LCVs. LidA
preferentially binds to activated Rab1, thus supporting the recruitment of
early secretory vesicles by SidM
(19,
20,
23,
25,
26). Another Icm/Dot
substrate, LepB (27),
contributes to Rab1-mediated membrane cycling by inactivating Rab1 through its
GTPase-activating protein function, thus acting as an antagonist of SidM
(24).The Icm/Dot substrate RalF recruits and activates the small GTPase
ADP-ribosylation factor 1 (Arf1), which is involved in retrograde vesicle
transport from Golgi to ER
(21). Dominant negative Arf1
(7,
28) or knockdown of Arf1 by
RNA interference (29) impairs
the formation of LCVs, as well as the recruitment of the Icm/Dot substrate
SidC to the LCV (30).SidC and its paralogue SdcA localize to the LCV membrane
(31), where the proteins
specifically bind to the host cell lipid phosphatidylinositol 4-phosphate
(PtdIns(4)P) (32,
33). Phosphoinositides (PIs)
regulate eukaryotic receptor-mediated signal transduction, actin remodeling,
and membrane dynamics (34,
35). PtdIns(4)P is present on
the cytoplasmic membrane, but localizes preferentially to the
trans-Golgi network (TGN), where this PI is produced by an
Arf-dependent recruitment of PtdIns(4)P kinase IIIβ (PI4K IIIβ)
(36) to promote trafficking
along the secretory pathway. Recently, PtdIns(4)P was found to also mediate
the export of early secretory vesicles from ER exit sites
(37). At present, the L.
pneumophila effector proteins that mediate exploitation of host PI
signaling remain ill defined.In a nonbiased screen for L. pneumophila PI-binding proteins using
different PIs coupled to agarose beads, we identified SidM as a major
PtdIns(4)P-binding effector. We mapped its PtdIns(4)P binding activity to a
novel P4M domain within a 12-kDa C-terminal sequence. SidM constructs,
including the P4M domain, were found to be translocated and bind the LCV
membrane, where the levels of PtdIns(4)P are controlled by PI4K IIIβ. 相似文献
18.
19.
Kuen-Feng Chen Pei-Yen Yeh Chiun Hsu Chih-Hung Hsu Yen-Shen Lu Hsing-Pang Hsieh Pei-Jer Chen Ann-Lii Cheng 《The Journal of biological chemistry》2009,284(17):11121-11133
Hepatocellular carcinoma (HCC) is one of the most common and aggressive
human malignancies. Recombinant tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is a promising anti-tumor agent. However,
many HCC cells show resistance to TRAIL-induced apoptosis. In this study, we
showed that bortezomib, a proteasome inhibitor, overcame TRAIL resistance in
HCC cells, including Huh-7, Hep3B, and Sk-Hep1. The combination of bortezomib
and TRAIL restored the sensitivity of HCC cells to TRAIL-induced apoptosis.
Comparing the molecular change in HCC cells treated with these agents, we
found that down-regulation of phospho-Akt (P-Akt) played a key role in
mediating TRAIL sensitization of bortezomib. The first evidence was that
bortezomib down-regulated P-Akt in a dose- and time-dependent manner in
TRAIL-treated HCC cells. Second, , a PI3K inhibitor, also sensitized
resistant HCC cells to TRAIL-induced apoptosis. Third, knocking down Akt1 by
small interference RNA also enhanced TRAIL-induced apoptosis in Huh-7 cells.
Finally, ectopic expression of mutant Akt (constitutive active) in HCC cells
abolished TRAIL sensitization effect of bortezomib. Moreover, okadaic acid, a
protein phosphatase 2A (PP2A) inhibitor, reversed down-regulation of P-Akt in
bortezomib-treated cells, and PP2A knockdown by small interference RNA also
reduced apoptosis induced by the combination of TRAIL and bortezomib,
indicating that PP2A may be important in mediating the effect of bortezomib on
TRAIL sensitization. Together, bortezomib overcame TRAIL resistance at
clinically achievable concentrations in hepatocellular carcinoma cells, and
this effect is mediated at least partly via inhibition of the PI3K/Akt
pathway.Hepatocellular carcinoma
(HCC) LY2940022 is currently
the fifth most common solid tumor worldwide and the fourth leading cause of
cancer-related death. To date, surgery is still the only curative treatment
but is only feasible in a small portion of patients
(1). Drug treatment is the
major therapy for patients with advanced stage disease. Unfortunately, the
response rate to traditional chemotherapy for HCC patients is unsatisfactory
(1). Novel pharmacological
therapy is urgently needed for patients with advanced HCC. In this regard, the
approval of sorafenib might open a new era of molecularly targeted therapy in
the treatment of HCC patients.Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a
type II transmembrane protein and a member of the TNF family, is a promising
anti-tumor agent under clinical investigation
(2). TRAIL functions by
engaging its receptors expressed on the surface of target cells. Five
receptors specific for TRAIL have been identified, including DR4/TRAIL-R1,
DR5/TRAIL-R2, DcR1, DcR2, and osteoprotegerin. Among TRAIL receptors, only DR4
and DR5 contain an effective death domain that is essential to formation of
death-inducing signaling complex (DISC), a critical step for TRAIL-induced
apoptosis. Notably, the trimerization of the death domains recruits an adaptor
molecule, Fas-associated protein with death domain (FADD), which subsequently
recruits and activates caspase-8. In type I cells, activation of caspase-8 is
sufficient to activate caspase-3 to induce apoptosis; however, in another type
of cells (type II), the intrinsic mitochondrial pathway is essential for
apoptosis characterized by cleavage of Bid and release of cytochrome
c from mitochondria, which subsequently activates caspase-9 and
caspase-3 (3).Although TRAIL induces apoptosis in malignant cells but sparing normal
cells, some tumor cells are resistant to TRAIL-induced apoptosis. Mechanisms
responsible for the resistance include receptors and intracellular resistance.
Although the cell surface expression of DR4 or DR5 is absolutely required for
TRAIL-induced apoptosis, tumor cells expressing these death receptors are not
always sensitive to TRAIL due to intracellular mechanisms. For example, the
cellular FLICE-inhibitory protein (c-FLIP), a homologue to caspase-8 but
without protease activity, has been linked to TRAIL resistance in several
studies (4,
5). In addition, inactivation
of Bax, a proapoptotic Bcl-2 family protein, resulted in resistance to TRAIL
in MMR-deficient tumors (6,
7), and reintroduction of Bax
into Bax-deficient cells restored TRAIL sensitivity
(8), indicating that the Bcl-2
family plays a critical role in intracellular mechanisms for resistance of
TRAIL.Bortezomib, a proteasome inhibitor approved clinically for multiple myeloma
and mantle cell lymphoma, has been investigated intensively for many types of
cancer (9). Accumulating
studies indicate that the combination of bortezomib and TRAIL overcomes the
resistance to TRAIL in various types of cancer, including acute myeloid
leukemia (4), lymphoma
(10–13),
prostate
(14–17),
colon (15,
18,
19), bladder
(14,
16), renal cell carcinoma
(20), thyroid
(21), ovary
(22), non-small cell lung
(23,
24), sarcoma
(25), and HCC
(26,
27). Molecular targets
responsible for the sensitizing effect of bortezomib on TRAIL-induced cell
death include DR4 (14,
27), DR5
(14,
20,
22–23,
28), c-FLIP
(4,
11,
21–23,
29), NF-κB
(12,
24,
30), p21
(16,
21,
25), and p27
(25). In addition, Bcl-2
family also plays a role in the combinational effect of bortezomib and TRAIL,
including Bcl-2 (10,
21), Bax
(13,
22), Bak
(27), Bcl-xL
(21), Bik
(18), and Bim
(15).Recently, we have reported that Akt signaling is a major molecular
determinant in bortezomib-induced apoptosis in HCC cells
(31). In this study, we
demonstrated that bortezomib overcame TRAIL resistance in HCC cells through
inhibition of the PI3K/Akt pathway. 相似文献
20.
Mikael K. Schnizler Katrin Schnizler Xiang-ming Zha Duane D. Hall John A. Wemmie Johannes W. Hell Michael J. Welsh 《The Journal of biological chemistry》2009,284(5):2697-2705
The acid-sensing ion channel 1a (ASIC1a) is widely expressed in central and
peripheral neurons where it generates transient cation currents when
extracellular pH falls. ASIC1a confers pH-dependent modulation on postsynaptic
dendritic spines and has critical effects in neurological diseases associated
with a reduced pH. However, knowledge of the proteins that interact with
ASIC1a and influence its function is limited. Here, we show that
α-actinin, which links membrane proteins to the actin cytoskeleton,
associates with ASIC1a in brain and in cultured cells. The interaction
depended on an α-actinin-binding site in the ASIC1a C terminus that was
specific for ASIC1a versus other ASICs and for α-actinin-1 and
-4. Co-expressing α-actinin-4 altered ASIC1a current density, pH
sensitivity, desensitization rate, and recovery from desensitization.
Moreover, reducing α-actinin expression altered acid-activated currents
in hippocampal neurons. These findings suggest that α-actinins may link
ASIC1a to a macromolecular complex in the postsynaptic membrane where it
regulates ASIC1a activity.Acid-sensing ion channels
(ASICs)2 are
H+-gated members of the DEG/ENaC family
(1–3).
Members of this family contain cytosolic N and C termini, two transmembrane
domains, and a large cysteine-rich extracellular domain. ASIC subunits combine
as homo- or heterotrimers to form cation channels that are widely expressed in
the central and peripheral nervous systems
(1–4).
In mammals, four genes encode ASICs, and two subunits, ASIC1 and ASIC2, have
two splice forms, a and b. Central nervous system neurons express ASIC1a,
ASIC2a, and ASIC2b
(5–7).
Homomeric ASIC1a channels are activated when extracellular pH drops below 7.2,
and half-maximal activation occurs at pH 6.5–6.8
(8–10).
These channels desensitize in the continued presence of a low extracellular
pH, and they can conduct Ca2+
(9,
11–13).
ASIC1a is required for acid-evoked currents in central nervous system neurons;
disrupting the gene encoding ASIC1a eliminates H+-gated currents
unless extracellular pH is reduced below pH 5.0
(5,
7).Previous studies found ASIC1a enriched in synaptosomal membrane fractions
and present in dendritic spines, the site of excitatory synapses
(5,
14,
15). Consistent with this
localization, ASIC1a null mice manifested deficits in hippocampal
long term potentiation, learning, and memory, which suggested that ASIC1a is
required for normal synaptic plasticity
(5,
16). ASICs might be activated
during neurotransmission when synaptic vesicles empty their acidic contents
into the synaptic cleft or when neuronal activity lowers extracellular pH
(17–19).
Ion channels, including those at the synapse often interact with multiple
proteins in a macromolecular complex that incorporates regulators of their
function (20,
21). For ASIC1a, only a few
interacting proteins have been identified. Earlier work indicated that ASIC1a
interacts with another postsynaptic scaffolding protein, PICK1
(15,
22,
23). ASIC1a also has been
reported to interact with annexin II light chain p11 through its cytosolic N
terminus to increase cell surface expression
(24) and with
Ca2+/calmodulin-dependent protein kinase II to phosphorylate the
channel (25). However, whether
ASIC1a interacts with additional proteins and with the cytoskeleton remain
unknown. Moreover, it is not known whether such interactions alter ASIC1a
function.In analyzing the ASIC1a amino acid sequence, we identified cytosolic
residues that might bind α-actinins. α-Actinins cluster membrane
proteins and signaling molecules into macromolecular complexes and link
membrane proteins to the actincytoskeleton (for review, Ref.
26). Four genes encode
α-actinin-1, -2, -3, and -4 isoforms. α-Actinins contain an
N-terminal head domain that binds F-actin, a C-terminal region containing two
EF-hand motifs, and a central rod domain containing four spectrin-like motifs
(26–28).
The C-terminal portion of the rod segment appears to be crucial for binding to
membrane proteins. The α-actinins assemble into antiparallel homodimers
through interactions in their rod domain. α-Actinins-1, -2, and -4 are
enriched in dendritic spines, concentrating at the postsynaptic membrane
(29–35).
In the postsynaptic membrane of excitatory synapses, α-actinin connects
the NMDA receptor to the actin cytoskeleton, and this interaction is key for
Ca2+-dependent inhibition of NMDA receptors
(36–38).
α-Actinins can also regulate the membrane trafficking and function of
several cation channels, including L-type Ca2+ channels,
K+ channels, and TRP channels
(39–41).To better understand the function of ASIC1a channels in macromolecular
complexes, we asked if ASIC1a associates with α-actinins. We were
interested in the α-actinins because they and ASIC1a, both, are present
in dendritic spines, ASIC1a contains a potential α-actinin binding
sequence, and the related epithelial Na+ channel (ENaC) interacts
with the cytoskeleton (42,
43). Therefore, we
hypothesized that α-actinin interacts structurally and functionally with
ASIC1a. 相似文献